Cargando…
Maintaining Surgical Treatment of Non-Small Cell Lung Cancer During the COVID-19 Pandemic in Paris
BACKGROUND: The coronavirus disease 2019 (COVID-19) outbreak was officially declared in France on March 14, 2020. The objective of this study is to report the incidence and outcome of COVID-19 after surgical resection of non-small cell lung cancer in Paris Public Hospitals during the pandemic. METHO...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
by The Society of Thoracic Surgeons Published by Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543779/ https://www.ncbi.nlm.nih.gov/pubmed/33038341 http://dx.doi.org/10.1016/j.athoracsur.2020.08.007 |
_version_ | 1783591732747698176 |
---|---|
author | Leclère, Jean-Baptiste Fournel, Ludovic Etienne, Harry Al Zreibi, Charbel Onorati, Ilaria Roussel, Arnaud Castier, Yves Martinod, Emmanuel Le Pimpec-Barthes, Françoise Alifano, Marco Assouad, Jalal Mordant, Pierre |
author_facet | Leclère, Jean-Baptiste Fournel, Ludovic Etienne, Harry Al Zreibi, Charbel Onorati, Ilaria Roussel, Arnaud Castier, Yves Martinod, Emmanuel Le Pimpec-Barthes, Françoise Alifano, Marco Assouad, Jalal Mordant, Pierre |
author_sort | Leclère, Jean-Baptiste |
collection | PubMed |
description | BACKGROUND: The coronavirus disease 2019 (COVID-19) outbreak was officially declared in France on March 14, 2020. The objective of this study is to report the incidence and outcome of COVID-19 after surgical resection of non-small cell lung cancer in Paris Public Hospitals during the pandemic. METHODS: We retrospective analyzed a prospective database including all patients who underwent non-small cell lung cancer resection between March 14, 2020, and May 11, 2020, in the 5 thoracic surgery units of Paris Public Hospitals. The primary endpoint was the occurrence of SARS-CoV-2 infection during the first 30 days after surgery. RESULTS: Study group included 115 patients (male 57%, age 64.6 ± 10.7 years, adenocarcinoma 66%, cT1 62%, cN0 82%). During the first month after surgery, 6 patients (5%) were diagnosed with COVID-19. As compared with COVID-negative patients, COVID-positive patients were more likely to be operated on during the first month of the pandemic (100% vs 54%, P = .03) and to be on corticosteroids preoperatively (33% vs 4%, P = .03). Postoperative COVID-19 was associated with an increased rate of readmission (50% vs 5%, P = .004), but no difference in 30-day morbidity (for the study group: grade 2, 24%; grade 3, 7%; grade 4, 1%) or mortality (n = 1 COVID-negative patient, 0.9%). Immediate oncologic outcomes did not differ significantly between groups (R0 resection 99%, nodal upstaging 14%, adjuvant chemotherapy 29%). CONCLUSIONS: During the COVID-19 pandemic, surgical treatment of non-small cell lung cancer was associated with a rate of postoperative COVID-19 of 5% with a significant impact on readmissions but not on other outcomes studied. |
format | Online Article Text |
id | pubmed-7543779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | by The Society of Thoracic Surgeons Published by Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-75437792020-10-09 Maintaining Surgical Treatment of Non-Small Cell Lung Cancer During the COVID-19 Pandemic in Paris Leclère, Jean-Baptiste Fournel, Ludovic Etienne, Harry Al Zreibi, Charbel Onorati, Ilaria Roussel, Arnaud Castier, Yves Martinod, Emmanuel Le Pimpec-Barthes, Françoise Alifano, Marco Assouad, Jalal Mordant, Pierre Ann Thorac Surg Original Article BACKGROUND: The coronavirus disease 2019 (COVID-19) outbreak was officially declared in France on March 14, 2020. The objective of this study is to report the incidence and outcome of COVID-19 after surgical resection of non-small cell lung cancer in Paris Public Hospitals during the pandemic. METHODS: We retrospective analyzed a prospective database including all patients who underwent non-small cell lung cancer resection between March 14, 2020, and May 11, 2020, in the 5 thoracic surgery units of Paris Public Hospitals. The primary endpoint was the occurrence of SARS-CoV-2 infection during the first 30 days after surgery. RESULTS: Study group included 115 patients (male 57%, age 64.6 ± 10.7 years, adenocarcinoma 66%, cT1 62%, cN0 82%). During the first month after surgery, 6 patients (5%) were diagnosed with COVID-19. As compared with COVID-negative patients, COVID-positive patients were more likely to be operated on during the first month of the pandemic (100% vs 54%, P = .03) and to be on corticosteroids preoperatively (33% vs 4%, P = .03). Postoperative COVID-19 was associated with an increased rate of readmission (50% vs 5%, P = .004), but no difference in 30-day morbidity (for the study group: grade 2, 24%; grade 3, 7%; grade 4, 1%) or mortality (n = 1 COVID-negative patient, 0.9%). Immediate oncologic outcomes did not differ significantly between groups (R0 resection 99%, nodal upstaging 14%, adjuvant chemotherapy 29%). CONCLUSIONS: During the COVID-19 pandemic, surgical treatment of non-small cell lung cancer was associated with a rate of postoperative COVID-19 of 5% with a significant impact on readmissions but not on other outcomes studied. by The Society of Thoracic Surgeons Published by Elsevier 2021-05 2020-10-08 /pmc/articles/PMC7543779/ /pubmed/33038341 http://dx.doi.org/10.1016/j.athoracsur.2020.08.007 Text en © 2021 by The Society of Thoracic Surgeons Published by Elsevier. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Leclère, Jean-Baptiste Fournel, Ludovic Etienne, Harry Al Zreibi, Charbel Onorati, Ilaria Roussel, Arnaud Castier, Yves Martinod, Emmanuel Le Pimpec-Barthes, Françoise Alifano, Marco Assouad, Jalal Mordant, Pierre Maintaining Surgical Treatment of Non-Small Cell Lung Cancer During the COVID-19 Pandemic in Paris |
title | Maintaining Surgical Treatment of Non-Small Cell Lung Cancer During the COVID-19 Pandemic in Paris |
title_full | Maintaining Surgical Treatment of Non-Small Cell Lung Cancer During the COVID-19 Pandemic in Paris |
title_fullStr | Maintaining Surgical Treatment of Non-Small Cell Lung Cancer During the COVID-19 Pandemic in Paris |
title_full_unstemmed | Maintaining Surgical Treatment of Non-Small Cell Lung Cancer During the COVID-19 Pandemic in Paris |
title_short | Maintaining Surgical Treatment of Non-Small Cell Lung Cancer During the COVID-19 Pandemic in Paris |
title_sort | maintaining surgical treatment of non-small cell lung cancer during the covid-19 pandemic in paris |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7543779/ https://www.ncbi.nlm.nih.gov/pubmed/33038341 http://dx.doi.org/10.1016/j.athoracsur.2020.08.007 |
work_keys_str_mv | AT leclerejeanbaptiste maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT fournelludovic maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT etienneharry maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT alzreibicharbel maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT onoratiilaria maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT rousselarnaud maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT castieryves maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT martinodemmanuel maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT lepimpecbarthesfrancoise maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT alifanomarco maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT assouadjalal maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT mordantpierre maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis AT maintainingsurgicaltreatmentofnonsmallcelllungcancerduringthecovid19pandemicinparis |